Skip to main content
Delfa

← Trials/Trial dossier/NCT01183806

CompletedPhase 3

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

Asset

Rivastigmine

Listed sites

2

Recruiting sites

-

Enrollment

40

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Patients' Quality of life

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01183806
Org study IDPA-01

Timeline

Milestones

Study start2010-07 (month precision)
Study first posted2010-08-18estimated
Primary completion2012-01actual (month precision)
Study completion2012-03actual (month precision)
Last update posted2012-03-20estimated

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Previous diagnosis of probable Alzheimer's disease
•At least 55 years of age
•Same caregiver (familiar or paid one) for at least 3 months before, who is able to follow the patient in a two-day/week exercise program
•Do not be taking other prescribed medication for Alzheimer disease
•Treated stable hypertension

Exclusion criteria

•Mini-Mental State Examination (MMSE) score of less than 12
•Can't follow simple commands;
•Can't answer two or more items of Quality of life questionnaire
•Practiced regular exercise or physiotherapy/ occupational therapy in the last two months.
•Diagnosed psychiatric condition (including depression).
•Use of neuroleptic drugs
•Orthopedic, neurologic, or behavioral limitations that may preclude exercise training
•Visual or hearing impairment that may preclude exercise training or comprehension

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Caregiver / quality of life
2
Global cognition
1
Function / daily living
1
Other clinical outcomes
1

Global cognition

1 endpoint
Secondary/protocol endpoint

Cognition

Time frame:Monthly for six months

Mini-Mental State Examination (MMSE)

descriptive

Function / daily living

1 endpoint
Secondary/protocol endpoint

Activities of daily living

Time frame:Monthly for six months

descriptive

Caregiver / quality of life

2 endpoints
Primary/protocol endpoint

Patients' Quality of life

Time frame:Monthly for six months

descriptive

Secondary/protocol endpoint

Caregivers' Quality of life

Time frame:Monthly for six months

descriptive

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

Functional mobility

Time frame:Monthly for six months

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.